London UK, 22 May 2006. Plasticell Ltd, the UK biotechnology company developing drugs to regenerate tissues of the body, has appointed Christopher Adam to its board. He will assist the company with corporate and product development strategies.
Mr Adam brings over 35 years of board level and operational experience in the pharmaceutical industry to Plasticell. He has sat on the executive committee of Glaxo Wellcome, the board of Glaxo Group Research, and at various times has served as President and CEO of Glaxo’s Japanese and French operations. Amongst other senior posts at Glaxo, he has held the positions of Director of Commercial Strategy, and Director of International Marketing.
Mr Adam holds a BSc in Biochemistry from University College London, and an EMBA from Stanford Business School. He was chairman of the European Business Community’s Pharmaceutical Committee representing European business interests in Japan, and is a Chevalier de la Légion d’Honneur, commended for services to the healthcare industry.
Dr Yen Choo, Plasticell’s Chief Executive, commented on the appointment: “I am delighted to welcome Chris to our board – his many achievements in big pharma are truly remarkable and I am convinced that his extensive strategic, operational and marketing experience will be invaluable as Plasticell enters a new phase of growth and goes forward to develop new medicines.”
Mr Adam added: “Stem cell research in general, and the technology platforms and research techniques developed by Plasticell in particular, offer exciting new horizons for innovative research to discover novel regenerative drugs. I am very excited about the company’s prospects.”
About Plasticell
Plasticell is a privately held, London-based biotechnology company using innovative, high throughput stem cell technologies and novel drug discovery platforms to dissect the mechanisms leading to differentiation of stem cells, the master cells responsible for tissue development and repair. Plasticell’s research focus is to discover regenerative small molecule drugs. The company also forms industry alliances by partnering its Combinatorial Cell Culture™ technology for high throughput stem cell differentiation, to derive cell lines for research and therapy applications. For more information please visit the company’s website: www.plasticell.co.uk